Tenax Therapeutics Inc
TENX6.150USD
-0.070-1.13%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
24.42MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Tenax Therapeutics Inc Unternehmen
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 (IV), TNX-102 (subcutaneous) and TNX-103 (oral) levosimendan. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
Unternehmensinformationen
BörsenkürzelTENX
Name des UnternehmensTenax Therapeutics Inc
IPO-datumOct 28, 1993
CEOMr. Christopher T. (Chris) Giordano
Anzahl der mitarbeiter4
WertpapierartOrdinary Share
GeschäftsjahresendeOct 28
Addresse101 Glen Lennox Drive
StadtCHAPEL HILL
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl27517
Telefon19198552100
Websitehttp://www.tenaxthera.com/
BörsenkürzelTENX
IPO-datumOct 28, 1993
CEOMr. Christopher T. (Chris) Giordano
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Stuart Rich, M.D.
Dr. Stuart Rich, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
2.65K
--
Dr. Declan Doogan, M.D.
Dr. Declan Doogan, M.D.
Independent Director
Independent Director
2.27K
--
Mr. Gerald T. (Gerry) Proehl
Mr. Gerald T. (Gerry) Proehl
Independent Chairman of the Board
Independent Chairman of the Board
1.67K
--
Mr. Thomas A. (Tom) Mcgauley
Mr. Thomas A. (Tom) Mcgauley
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Dr. June Almenoff, M.D., Ph.D.
Dr. June Almenoff, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Christopher T. (Chris) Giordano
Mr. Christopher T. (Chris) Giordano
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Robyn M. Hunter
Ms. Robyn M. Hunter
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Stuart Rich, M.D.
Dr. Stuart Rich, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
2.65K
--
Dr. Declan Doogan, M.D.
Dr. Declan Doogan, M.D.
Independent Director
Independent Director
2.27K
--
Mr. Gerald T. (Gerry) Proehl
Mr. Gerald T. (Gerry) Proehl
Independent Chairman of the Board
Independent Chairman of the Board
1.67K
--
Mr. Thomas A. (Tom) Mcgauley
Mr. Thomas A. (Tom) Mcgauley
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Dr. June Almenoff, M.D., Ph.D.
Dr. June Almenoff, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Christopher T. (Chris) Giordano
Mr. Christopher T. (Chris) Giordano
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, May 16
Aktualisiert: Fri, May 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
RTW Investments L.P.
9.12%
The Lind Partners, LLC
9.04%
Dellora Investments LP
8.46%
BVF Partners L.P.
8.18%
Millennium Management LLC
5.63%
Other
59.56%
Aktionäre
Aktionäre
Anteil
RTW Investments L.P.
9.12%
The Lind Partners, LLC
9.04%
Dellora Investments LP
8.46%
BVF Partners L.P.
8.18%
Millennium Management LLC
5.63%
Other
59.56%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
30.53%
Investment Advisor/Hedge Fund
18.96%
Venture Capital
10.04%
Investment Advisor
9.19%
Research Firm
2.85%
Individual Investor
0.23%
Other
28.19%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
58
2.98M
71.81%
+994.85K
2025Q1
58
2.74M
66.20%
+755.49K
2024Q4
56
1.98M
58.13%
+213.72K
2024Q3
58
1.98M
66.48%
+633.55K
2024Q2
48
161.28K
18.23%
+129.16K
2024Q1
48
149.68K
17.63%
+121.80K
2023Q4
43
26.36K
16.08%
+6.23K
2023Q3
45
17.13K
13.16%
+882.00
2023Q2
48
14.32K
12.38%
-2.77K
2023Q1
49
16.81K
20.77%
+6.69K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
RTW Investments L.P.
378.35K
9.12%
+378.35K
--
Mar 31, 2025
The Lind Partners, LLC
375.00K
9.04%
+305.00K
+435.71%
Sep 30, 2024
Dellora Investments LP
351.07K
8.46%
--
--
Mar 05, 2025
BVF Partners L.P.
339.55K
8.18%
--
--
Mar 31, 2025
Millennium Management LLC
233.62K
5.63%
+206.99K
+777.40%
Jun 26, 2025
VR Adviser, LLC
208.33K
5.02%
--
--
Mar 31, 2025
Vivo Capital, LLC
208.33K
5.02%
--
--
Mar 31, 2025
Integral Health Asset Management, LLC
167.00K
4.03%
+167.00K
--
Mar 31, 2025
Janus Henderson Investors
166.67K
4.02%
--
--
Mar 31, 2025
Morgan Stanley & Co. LLC
117.83K
2.84%
+45.66K
+63.27%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
DFA Dimensional US Sustainability Core 1 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Dec 29, 2023
Merger
80<1
Dec 29, 2023
Merger
80<1
Dec 29, 2023
Merger
80<1
Dec 29, 2023
Merger
80<1
Jan 04, 2023
Merger
20<1
Jan 04, 2023
Merger
20<1
Datum
Art
Verhältnis
Dec 29, 2023
Merger
80<1
Dec 29, 2023
Merger
80<1
Dec 29, 2023
Merger
80<1
Dec 29, 2023
Merger
80<1
Jan 04, 2023
Merger
20<1
Jan 04, 2023
Merger
20<1
Jan 04, 2023
Merger
20<1
Jan 04, 2023
Merger
20<1
